Upon joining the study, you will be informed about the trial’s purpose, which is to examine the effect on all-cause mortality at 90 days of a range of interventions in patients with Staphylococcus aureus bacteremia.

You will be asked to provide consent to participate in the trial, acknowledging that you understand the procedures and potential risks involved.

An initial assessment will be conducted to confirm that Staphylococcus aureus has been grown from at least one blood culture.

You must be admitted to a participating hospital at the time of this assessment.

You will be randomly assigned to receive one of the following medications: rifampicin, doxycycline, co-trimoxazole, cefazolin, flucloxacillin, daptomycin, benzylpenicillin sodium, amoxicillin, levofloxacin, clindamycin, cefalexin, moxifloxacin, linezolid, clindamycin hydrochloride, or vancomycin.

The route of administration will vary depending on the medication, including oral, intravenous, or IV infusion.

You will receive the assigned medication according to the specified dosage and frequency, which will be explained to you by the medical team.

The duration of administration will be determined based on your response to the treatment and the study protocol.

Throughout the trial, your health will be closely monitored to assess the effectiveness of the treatment and to identify any side effects.

Follow-up assessments will occur at 14, 28, 42, and 90 days after entering the trial to evaluate your health status and any changes in your condition.

At the end of the 90-day period, a final assessment will be conducted to determine the overall outcome of the treatment.

You will be informed about the results of the trial and any further steps that may be necessary for your health care.